• Type:
  • Category:

BRAIN Biotech AG | Financials: H1-2022 | Michael Schneiders, IR
Share

Chapters

00:19  Brain at a Glance

01:05  Group Overview

01:58  Q2-Highlights

04:05  ESG+: 5 Key Points

05:14  ESG+ Targets 2032/2050

06:54  The ESG Opportunity 

07:58  Brain Incubator

09:02  Urban Mining Project

10:11  Genome Editing

12:06  H1 2021/22 Financial Highlights

13:22  Cash & Cash Flow

14:18  Long-Term Revenue Growth Trajectory

14:52  Covid, Supply Chain and Inflation

15:45  FY21/22 Guidance, Mid-Term Targets

Attachments

BRAIN Biotech AG
Darmstaedter Strasse 34-36
64673 Zwingenberg
Germany

 

phone +49 6251 9331 86

Company Profile

BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group’s business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.

 

The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.

 

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.

 

Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

Featuring

Michael Schneiders
Head of Investor Relations | BRAIN Biotech AG​

More Elevator Pitches

More Company Presentations

Reviews for

BRAIN Biotech AG | Financials: H1-2022 | Michael Schneiders, IR
There are currently no reviews for
BRAIN Biotech AG | Financials: H1-2022 | Michael Schneiders, IR
Scroll to top